GenSight Biologics Overview
- Year Founded
-
2012
- Status
-
Public
- Employees
-
13
- Stock Symbol
-
SIGHT
- Share Price
-
$0.08
- (As of Friday Closing)
GenSight Biologics General Information
Description
Gensight Biologics SA is a clinical-stage biopharma company focused on developing and commercializing gene therapies for retinal neurodegenerative diseases and central nervous system disorders. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.
Contact Information
Website
www.gensight-biologics.comCorporate Office
- 74 Rue du Faubourg
- Saint-Antoine
- 75012 Paris
- France
Corporate Office
- 74 Rue du Faubourg
- Saint-Antoine
- 75012 Paris
- France
GenSight Biologics Timeline
GenSight Biologics Stock Performance
As of 13-Nov-2026, GenSight Biologics’s stock price is $0.08. Its current market cap is $20.3M with 245M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.08 | $0.08 | $0.07 - $0.17 | $20.3M | 245M | 1.69M | -$0.09 |
GenSight Biologics Financials Summary
As of 30-Jun-2026, GenSight Biologics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 33,510 | 43,534 | 43,871 | 49,693 |
| Revenue | 1 | 1,623 | 1,371 | |
| EBITDA | (14,136) | (9,805) | (12,303) | (22,605) |
| Net Income | (17,894) | (13,577) | (15,150) | (28,372) |
| Total Assets | 7,394 | 9,698 | 11,192 | 10,095 |
| Total Debt | 14,658 | 15,109 | 14,998 | 20,370 |
GenSight Biologics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
GenSight Biologics Comparisons
Industry
Financing
Details
GenSight Biologics Competitors (36)
One of GenSight Biologics’s 36 competitors is Neurogene, a Formerly VC-backed company based in New York, NY.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Neurogene | Formerly VC-backed | New York, NY | ||||
| CuraSen | Venture Capital-Backed | San Carlos, CA | ||||
| Alector | Formerly VC-backed | South San Francisco, CA | ||||
| Prevail Therapeutics | Formerly VC-backed | New York, NY | ||||
| Sangamo Therapeutics | Formerly VC-backed | Richmond, CA |
GenSight Biologics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
GenSight Biologics Patents
GenSight Biologics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024264771-A1 | Method for controlling the illumination of a surface of an object by a projecting unit and associated method and devices | Pending | 04-May-2023 | ||
| EP-4704972-A1 | Method for controlling the illumination of a surface of an object by a projecting unit and associated method and devices | Pending | 04-May-2023 | ||
| WO-2024227926-A1 | Method for controlling the illumination of a surface of an object by a projecting unit and associated method and devices | Inactive | 04-May-2023 | ||
| AU-2024264802-A1 | Viewing apparatus | Pending | 04-May-2023 | ||
| EP-4705823-A1 | Viewing apparatus | Pending | 04-May-2023 | G02B27/0172 |
GenSight Biologics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
GenSight Biologics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
GenSight Biologics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
GenSight Biologics FAQs
-
When was GenSight Biologics founded?
GenSight Biologics was founded in 2012.
-
Where is GenSight Biologics headquartered?
GenSight Biologics is headquartered in Paris, France.
-
What is the size of GenSight Biologics?
GenSight Biologics has 13 total employees.
-
What industry is GenSight Biologics in?
GenSight Biologics’s primary industry is Biotechnology.
-
Is GenSight Biologics a private or public company?
GenSight Biologics is a Public company.
-
What is GenSight Biologics’s stock symbol?
The ticker symbol for GenSight Biologics is SIGHT.
-
What is the current stock price of GenSight Biologics?
As of 13-Nov-2026 the stock price of GenSight Biologics is $0.08.
-
What is the current market cap of GenSight Biologics?
The current market capitalization of GenSight Biologics is $20.3M.
-
Who are GenSight Biologics’s competitors?
Neurogene, CuraSen, Alector, Prevail Therapeutics, and Sangamo Therapeutics are some of the 36 competitors of GenSight Biologics.
-
What is GenSight Biologics’s annual earnings per share (EPS)?
GenSight Biologics’s EPS for 12 months was -$0.09.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
